This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
The Enzo Clinical Labs subsidiary of Enzo Biochem, Inc. (NYSE:ENZ) has entered into an agreement to market in its northeast U.S. service area a proprietary early non-invasive prenatal laboratory test (“LDT”) service, MaterniT21 PLUS ™, developed by the Sequenom Laboratories, Inc., subsidiary of Sequenom, Inc. (NASDAQ:SQNM).
“The addition of Sequenom Laboratories’ innovative prenatal testing service provides an important complement to our extensive menu of women’s health diagnostic assays, and also is testament to the strong and growing capabilities in the general and rapidly developing area of diagnostics resulting from integration of Enzo’s Life Sciences and Clinical Labs,” said Barry Weiner, Enzo President.
Mr. Weiner added, “Sequenom Laboratories’ testing service will be of great value to our physician clients and their patients, providing an advanced crucial assay to assess the potential for chromosomal abnormalities early in a pregnancy. It also underscores our Company’s leading independent position in a highly valuable regional market for clinical laboratory services, and our expertise in the development and marketing of high-value esoteric testing that provides an excellent vehicle through which we can offer this, as well as our growing menu of ground breaking diagnostic assays.”
Sequenom Laboratories was the first to market a noninvasive prenatal laboratory-developed test for fetal chromosomal abnormalities. The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. The test is intended for use in pregnant women at increased risk for fetal aneuploidy, can be used as early as 10 weeks' gestation, and is run exclusively by Sequenom Center for Molecular Medicine, doing business as Sequenom Laboratories Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.